NSAIDs and Cardiovascular Effects News Index

 
 
  • Vioxx Critique Will Not Scuttle Merck Settlement Renewed criticism of Merck & Co's handling of its withdrawn pain drug Vioxx is not about to scuttle the multibillion-dollar deal to settle thousands of personal injury lawsuits brought by former Vioxx users, plaintiffs' attorneys and the drugmaker said.
    Reuters Health Information, April 2008
  • CME/CE New Data Will Help Guide Prescribing of Celecoxib A meta-analysis of 6 trials involving celecoxib may provide a measure of comfort to clinicians prescribing the cyclooxygenase-2 inhibitor to patients at low risk for cardiovascular disease.
    Medscape Medical News, April 2008
  • No Increase in Hemorrhagic Stroke Risk Seen With Nonaspirin NSAIDs Taking nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) does not appear to increase the risk of hemorrhagic stroke, according to a study by Korean investigators reported in the March issue of Stroke.
    Reuters Health Information, March 2008
  • NSAID-Related Ulcer Rate Declines in RA Patients The Netherlands has seen a decline in non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and related complications in patients with rheumatoid arthritis, mirroring declines seen in the US, researchers report in the Annals of the Rheumatic Diseases for February.
    Reuters Health Information, March 2008
  • CME/CE Use of Multiple NSAIDs Reduces Arthritis Pain but May Increase Complications Patients taking over-the-counter and prescription nonsteroidal anti-inflammatory drugs had reduced pain during daily activities, but taking both drugs for symptom relief may increase complications.
    Medscape Medical News, February 2008
  • Parecoxib Safe in Patients With NSAID Hypersensitivity The injectable COX-2 inhibitor parecoxib appears to be safe to use in people with non-steroidal anti-inflammatory drug (NSAID)-induced urticaria or angioedema, according to Italian researchers.
    Reuters Health Information, February 2008
  • CME/CE NSAIDs May Not Be Best Bet for Low Back Pain A review of the literature on relief for low back pain suggests that nonsteroidal anti-inflammatory drugs are no more effective than acetaminophen or other treatments.
    Medscape Medical News, January 2008
  • CME NSAIDs Safe for Pain Control After Tonsillectomy in Children A study shows that perioperative use of nonsteroidal anti-inflammatory drugs does not increase the risk for postoperative bleeding after tonsillectomy or adenotonsillectomy in pediatric patients.
    Reuters Health Information, January 2008
  • What Your Patients Are Reading: Moderate Caffeine Intake Associated With Increased Miscarriage Risk Recent news stories have examined the link between moderate caffeine intake and risk for miscarriage, the prevention of urinary tract infections with cranberries, use of NSAIDs for low back pain, the link between fitness levels and all-cause mortality, and use of prednisone for rheumatoid arthritis.
    Medscape Medical News, January 2008
  • Pfizer Wins Ruling That May Limit Celebrex Suits Pfizer Inc has won a U.S. court ruling that could limit the lawsuits claiming that its Celebrex painkiller caused heart attacks and strokes.
    Reuters Health Information, November 2007
  • Merck Agrees to Pay $4.85 Bln in Vioxx Settlement Merck & Co has agreed to pay $4.85 billion to settle claims that its painkiller Vioxx caused heart attacks and strokes in thousands of users, the drugmaker said on Friday.
    Reuters Health Information, November 2007
  • CME NSAID Use Associated With Reduced Risk for Parkinson's Disease Researchers say their new study adds to a growing body of evidence that nonsteroidal anti-inflammatory drugs may have a protective effect against the development of Parkinson's disease.
    Medscape Medical News, November 2007
  • Risk of GI Bleeding Increased When NSAIDs and SSRIs Are Taken Together Selective serotonin reuptake inhibitors (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) can interact to increase the risk of upper gastrointestinal bleeding, according to a report in the October 5th issue of Alimentary Pharmacology and Therapeutics.
    Reuters Health Information, October 2007
  • CME Breast Cancer Risk May Decrease With Increasing Duration of NSAID Use A case-control study shows that risk is generally lowest for 7 years or more of use of nonsteroidal anti-inflammatory drugs, and both aspirin and nonaspirin use was associated with reduced risks.
    Medscape Medical News, October 2007
  • Mouse Study Suggests Mechanism Behind COX-2-Inhibitor Cardiovascular Risk Researchers suggest that blocking the COX pathway triggers a cascade of events that leads to an increase in the amount of circulating tissue factor, an initiator of coagulation.
    Heartwire, August 2007
  • Australia Bans Novartis's Prexige on Liver Worries Australia's drugs regulator banned the use of Novartis's Prexige because of liver problems in patients using the painkiller, the watchdog said, including two deaths and two liver transplants.
    Reuters Health Information, August 2007
  • NSAIDs Variably Affect Cardiovascular Outcomes Different nonsteroidal anti-inflammatory drugs (NSAIDs) confer different thrombotic risk in patients with osteoarthritis, and risk varies depending on use of aspirin to prevent cardiovascular events, according to a report in the June issue of the Annals of the Rheumatic Diseases.
    Reuters Health Information, July 2007
  • CME Celecoxib Noninferior to Diclofenac for Short-Term Pain Relief in Ankylosing Spondylitis A randomized trial showed 200 mg of celecoxib either once or twice daily appeared comparable to 75 mg of diclofenac twice daily in reducing pain in patients with ankylosing spondylitis.
    Medscape Medical News, July 2007
  • Nabumetone and Meloxicam Well Tolerated in NSAID-Intolerant Subjects Nabumetone and meloxicam appear to be safe alternatives for patients intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs), based on findings reported in the April issue of the Journal of Allergy and Clinical Immunology.
    Reuters Health Information, May 2007
  • FDA Advisory Panel Votes "No" to Etoricoxib Merck's new arthritis drug--another COX-2 inhibitor--was shut out 19-1 by the mixed FDA panel. Some members argued passionately that it was time to drop the class of drugs, due primarily to their cardiovascular risk profile.
    Heartwire, April 2007
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.